Impact of GSE and Xylitol (Xlear) on COVID-19 Symptoms and Time to PCR Negativisation in COVID-19 Patients

Phase 3

Withdrawn

• Conditions: Covid19
• Interventions: Drug: Control Placebo; Other: GSE and Xylitol

• Registration Number: NCT04854486
• Lead Sponsor: Larkin Community Hospital

Brief Summary

This clinical trial aims to ascertain the impact of GSE and Xylitol (XLEAR) in decreasing the time of negativisation in PCR testing in patients with COVID-19.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-04-17
• Study First Submitted QC: 2021-04-17
• Study First Posted: 2021-04-22
• Study Start: 2021-12-16
• Primary Completion: 2022-03-30
• Study Completion: 2022-11-16
• Status Verified: 2023-10
• Last Update Submitted: 2023-10-12
• Last Update Posted: 2023-10-16

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Control placebo	Control Placebo	Saline
Treatment Group	GSE and Xylitol	Xylitol + GSE

Primary Outcome Measures

Name	Time	Method
Change of time to negativisation via PCR	Baseline and 7 days	There will be a change in the time to negativisation via PCR as compared to the average 14-day time to negative result.

Trial Locations

Locations (2)

Larkin Community Hospital Palm Springs Campus; 🇺🇸 Miami, Florida, United States

Larkin Community Hospital; 🇺🇸 Miami, Florida, United States